New Blood Test Predicts Breast Cancer Relapse Months in Advance

Researchers from The Institute of Cancer Research in London have developed a new blood test, or a so-called liquid biopsy, that can detect breast cancer relapse months in advance compared to traditional scans. The technology, published in journal Science Translational Medicine, measures the level of circulating tumor DNA (ctDNA), the DNA that has been shed by circulating tumor cells, in plasma isolated from blood. By measuring the level of genetic mutations in the ctDNA, the test can predict the nature of metastatic disease and can inform doctors about the potential treatments that could be targeted to address the genetic mutations.